此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

术前额外使用阿奇霉素是否会减少子宫切除术后感染

2026年9月19日 更新者:Päivi Rahkola-Soisalo、Helsinki University Central Hospital

子宫切除术后感染——一项比较阿奇霉素和头孢呋辛预防性使用与单一头孢呋辛预防性使用的安慰剂对照研究

During hysterectomy bacteria may enter into the peritoneal cavity through vaginal opening and contaminate the healing tissues. The risk for deep infection after hysterectomy is about 5%. By reducing post-hysterectomy infections, it is possible to reduce individual burden of disease in addition to the direct and indirect financial costs. This study primary aim is to assess if prophylactic preoperative use of azithromycin in addition to generally used cefuroxime decreases post-hysterectomy infections as compared to cefuroxime only prophylaxis during 30 days after hysterectomy. Secondary aim is to assess if there is change in post-hysterectomy superficial infections, urinary tract infections, or post-operative fever between the cohorts and to report possible side-effects of the used antibiotics. In addition, the study finds out a possible role of bacterial vaginosis and microbiome n post-hysterectomy infections.

研究概览

研究类型

介入性

注册 (估计的)

2278

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Helsinki、芬兰
        • 招聘中
        • Helsinki University Central Hospital
        • 接触:
        • 接触:
        • 副研究员:
          • Liisu Saavalainen, PhD, MD
        • 副研究员:
          • Päivi Härkki, Adj prof, MD
        • 副研究员:
          • Tomi Mikkola, Prof, MD
        • 副研究员:
          • Veli-Jukka Anttila, Adj prof,MD
        • 副研究员:
          • Seppo Virtanen, DI, MD
        • 副研究员:
          • Anne Saloranta, Adj Prof
        • 副研究员:
          • Ilkka Kalliala, Adj Prof, MD
        • 副研究员:
          • Suvi Niku, PhD, MD
      • Jyväskylä、芬兰、40620
        • 招聘中
        • Jyväskylä Central Hospital
        • 接触:
      • Kuopio、芬兰、70029
        • 招聘中
        • Kuopio University Central Hospital
        • 接触:
      • Oulu、芬兰、PL23
        • 招聘中
        • Oulu University Central Hospital
        • 接触:
      • Tampere、芬兰、33521
        • 招聘中
        • Tampere University Central Hospital
        • 接触:
        • 副研究员:
          • Elina Ylilehto, PhD, MD
      • Turku、芬兰
        • 招聘中
        • Turku University Central Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Women undergoing hysterectomy for benign indication in University Hospitals (Helsinki University Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital and Kuopio University Hospital) who have not any contraindications for azithromycin or cefuroxime.

Exclusion Criteria:

  • Inability to understand the study protocol.
  • Allergy for either cefuroxime or azithromycin.
  • Congenital or acquired prolonged Q-T-corrected interval. All the participants will be asked about arrhythmias and whether they have congenital arrhythmias in the family,
  • Electrocardiogram will be checked for all the participants.
  • Use of medicines that may prolong Q-T-corrected interval (class Ia arrhythmia medications, quinidine, procainamide, and class III arrhythmia medications dofetilide, amiodarone and sotalol).
  • Use of selective serotonin reuptake inhibitor medication and prolonged Q-T-corrected interval.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Azithromycin + Cefuroxime

Changed with renewed study permissions:

These patients will receive Azithromycin 500 mg (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more) in the operating theatre before the incision.

The previous description:

These patients will receive Azithromycin 500 mg (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision.

Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision

有源比较器:Placebo + Cefuroxime

Changed with new study permissions:

These patients will receive placebo (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more)in the operating theatre before the incision.

The previous description:

These patients will receive placebo (2 tablets) per orally in the evening before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision.

Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of post-hysterectomy episodes with deep infections
大体时间:Deep infections that occur between the first and 30th postoperative day after hysterectomy

Number of deep wound and pelvic organ infection episodes reported by patients and doctors

Deep infections that occur between the first and 30th postoperative day after hysterectomy

次要结果测量

结果测量
措施说明
大体时间
Number of other post-hysterectomy infections or fever episodes
大体时间:Number of other infections or fever episodes that occur between the first and 30th postoperative day after hysterectomy.

Number of superficial infections, other infections, such has urine tract infections, or fever episodes lasting over 38 ℃ over 2 days

Number of other infections or fever episodes that occur between the first and 30th postoperative day after hysterectomy.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Päivi Rahkola-Soisalo, Adj prof, MD、Helsinki University Central Hospital
  • 学习椅:Tomi Mikkola, Prof, MD、Helsinki University Central Hospital
  • 研究主任:Päivi Rahkola-Soisalo, Adj prof, MD、Helsinki University Central Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年9月5日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2030年12月31日

研究注册日期

首次提交

2022年4月14日

首先提交符合 QC 标准的

2022年4月14日

首次发布 (实际的)

2022年4月20日

研究记录更新

最后更新发布 (实际的)

2026年9月22日

上次提交的符合 QC 标准的更新

2026年9月19日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅